“…Several studies showed that patients with higher tumor grade had worse PFS [ 348 , 349 , 356 , 359 ] and OS [ 342 , 347 , 348 , 349 , 351 , 354 , 356 , 357 ] with liver-directed therapies, particularly in patients with G3 tumors [ 342 , 347 , 349 , 357 ]. Pathologic factors predicting worse outcomes with liver-directed therapies include high hepatic tumor burden [ 342 , 347 , 348 , 349 , 352 , 354 , 357 , 358 , 361 , 365 ] ( Table 5 ).…”